U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie
U.S. STOCKS ON THE MOVE-Fortinet, KB Home, Goldman Sachs
U.S. STOCKS ON THE MOVE-Teladoc Health, Mustang Bio, Instacart
Mustang Bio falls after announcement of reverse stock split
Brief: Mustang Bio Says On Nov 12, James Murphy Resigned As Interim CFO
Brief: Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy
Brief: Mustang Bio Inc Files For Mixed Shelf Of Up To $40 Million – SEC Filing
Brief: Mustang Bio Inc - On May 16 Got Notice From Nasdaq
Brief: Mustang Bio Announces Pricing Of $4 Million Public Offering
Brief: Mustang Bio Approves Reduction Of Workforce By About 81% Of Its Employee Base
Brief: Mustang Bio Expands Into Autoimmune Diseases With CAR T-Cell Therapy Platform
Brief: Mustang Bio Received Letter From Nasdaq Notifying Co Was Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Health Rounds: CAR-T therapy shows early promise against brain cancer
Brief: Mustang Bio Announces Publication Of Data From Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells In High-Grade Glioma
Brief: Mustang Bio Appoints James Murphy As Interim Chief Financial Officer